5:29 PM
 | 
Sep 25, 2009
 |  BC Extra  |  Company News

Folotyn gets accelerated approval

FDA granted accelerated approval to an NDA for Folotyn pralatrexate from Allos Therapeutics Inc. (NASDAQ:ALTH) to treat relapsed or...

Read the full 88 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >